NCAM1 and acute myeloid leukemia: Specifically, some of them were shown to offer additional adverse prognostic value to current stratification strategy, such as CD25 and CD56 in cytogenetically intermediate-risk AML [5, 48] and CD56 in AML with t(8;21);AML1/ETO or with t(15;17);PML/RARA [14, 49].